---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-066995"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:23:33.335550+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics gets Nasdaq transfer to Capital Market and 180-day bid-price extension

## Summary
- Nasdaq approved transfer to Capital Market effective July 24, 2025.
- Company granted until January 19, 2026 to regain $1 minimum bid price compliance.
- Must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.
- Company intends to monitor bid price and take reasonable measures to maintain listing.

## SEC filing metadata
- accession: 0001213900-25-066995
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/0001213900-25-066995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/ea0249919-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-066995
- JSON: https://secwatch.observer/filing/0001213900-25-066995.json
- Plain text: https://secwatch.observer/filing/0001213900-25-066995.txt

## Key facts
- Listing & Compliance Notices
  RELMADA THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 22, 2025, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025. Nasdaq also approved a 180-day extension, or until January 19, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price in accordance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/0001213900-25-066995-index.htm
- Listing & Compliance Notices
  RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5810(c)(3)(A)
  source text: January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had a compliance period of 180 calendar days from the date of the notice (“Initial Compliance Period”), and that it may regain compliance if the closing bid of t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/0001213900-25-066995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.